A randomized phase II study of the combination of 5-azacytidine with valproic acid versus low-dose ara-C [cytarabine] in patients with AML/MDS [acute myeloid leukaemia/myelodysplastic syndromes] not eligible for other studies.

Trial Profile

A randomized phase II study of the combination of 5-azacytidine with valproic acid versus low-dose ara-C [cytarabine] in patients with AML/MDS [acute myeloid leukaemia/myelodysplastic syndromes] not eligible for other studies.

Completed
Phase of Trial: Phase II

Latest Information Update: 06 Aug 2012

At a glance

  • Drugs Azacitidine (Primary) ; Valproic acid (Primary) ; Cytarabine
  • Indications Acute myeloid leukaemia; Myelodysplastic syndromes
  • Focus Therapeutic Use
  • Most Recent Events

    • 14 Apr 2011 Status changed from discontinued to completed, according to ClincialTrials.gov record.
    • 11 Aug 2009 Status changed from completed to discontinued as reported by ClinicalTrials.gov.
    • 26 Jan 2009 Status changed from active, no longer recruiting to completed, according to ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top